111 Capital Invests $325,000 in Alignment Healthcare, Inc. $ALHC

111 Capital bought a new position in shares of Alignment Healthcare, Inc. (NASDAQ:ALHC) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 23,223 shares of the company’s stock, valued at approximately $325,000.

A number of other institutional investors have also modified their holdings of ALHC. Two Sigma Investments LP purchased a new position in shares of Alignment Healthcare during the fourth quarter worth approximately $258,000. GAMMA Investing LLC increased its position in shares of Alignment Healthcare by 3,216.9% during the first quarter. GAMMA Investing LLC now owns 23,815 shares of the company’s stock worth $443,000 after acquiring an additional 23,097 shares during the period. Rhumbline Advisers increased its position in shares of Alignment Healthcare by 4.4% during the first quarter. Rhumbline Advisers now owns 141,638 shares of the company’s stock worth $2,637,000 after acquiring an additional 5,934 shares during the period. Assenagon Asset Management S.A. increased its position in shares of Alignment Healthcare by 478.0% during the first quarter. Assenagon Asset Management S.A. now owns 831,397 shares of the company’s stock worth $15,481,000 after acquiring an additional 687,566 shares during the period. Finally, Blue Trust Inc. increased its position in shares of Alignment Healthcare by 2,748.5% during the first quarter. Blue Trust Inc. now owns 24,867 shares of the company’s stock worth $463,000 after acquiring an additional 23,994 shares during the period. 86.19% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Alignment Healthcare news, insider Robert L. Scavo sold 29,535 shares of Alignment Healthcare stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $16.41, for a total value of $484,669.35. Following the transaction, the insider directly owned 572,555 shares of the company’s stock, valued at approximately $9,395,627.55. The trade was a 4.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Dawn Christine Maroney sold 215,662 shares of Alignment Healthcare stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $16.41, for a total transaction of $3,539,013.42. Following the completion of the transaction, the president directly owned 1,797,237 shares in the company, valued at $29,492,659.17. This represents a 10.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 7,388,173 shares of company stock valued at $118,068,256. 6.60% of the stock is currently owned by company insiders.

Alignment Healthcare Price Performance

NASDAQ ALHC opened at $17.11 on Tuesday. The firm’s fifty day simple moving average is $15.70 and its two-hundred day simple moving average is $15.65. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 2.29. Alignment Healthcare, Inc. has a 12-month low of $10.11 and a 12-month high of $21.06. The firm has a market capitalization of $3.39 billion, a P/E ratio of -61.10 and a beta of 1.18.

Alignment Healthcare (NASDAQ:ALHC) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.14. Alignment Healthcare had a negative net margin of 1.53% and a negative return on equity of 43.68%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $960.25 million. During the same period in the previous year, the company earned ($0.13) earnings per share. The business’s revenue for the quarter was up 49.0% on a year-over-year basis. Alignment Healthcare has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Analysts forecast that Alignment Healthcare, Inc. will post -0.69 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ALHC shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alignment Healthcare in a research report on Saturday, September 27th. KeyCorp upgraded Alignment Healthcare from a “sector weight” rating to an “overweight” rating and set a $21.00 target price for the company in a report on Monday, August 25th. Wall Street Zen downgraded Alignment Healthcare from a “buy” rating to a “hold” rating in a report on Sunday, August 10th. Barclays upgraded Alignment Healthcare from an “underweight” rating to an “equal weight” rating and upped their price objective for the stock from $9.00 to $13.00 in a research note on Thursday, July 31st. Finally, Zacks Research upgraded Alignment Healthcare from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 29th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $18.83.

Alignment Healthcare Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.